Anca Chiriac, MD
Cardiovascular Disease · Jacksonville, FLNPI 1134448020
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (52.8%), food and beverage and grants — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Medtronic at 46.0% of the total. Reporting peaked in 2022 at $4,884 and has fallen 85.9% since, to $691 in 2025.
Across 90 payments — averaging $141.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Abbott$3K
- Medical Device Business Services, Inc.$3K
- Biosense Webster, Inc.$453
- Boston Scientific$348
- Merit Medical Systems Inc$114
What the payments were for
- Grants$2,00016%
- Travel & lodging$6,74153%
- Food & beverage$2,94823%
- Education$1,0788%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 25 | $5,870 |
| Abbott | 31 | $3,409 |
| Medical Device Business Services, Inc. | 25 | $2,573 |
| Biosense Webster, Inc. | 4 | $453 |
| Boston Scientific | 4 | $348 |
| Merit Medical Systems Inc | 1 | $114 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,767 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $67,524 |
| XareltoRivaroxaban | 25 | $32,039 |
| MultaqDronedarone Hcl | 11 | $13,303 |
| Amiodarone Hcl | 26 | $1,213 |
| Metoprolol Succinate | 30 | $976 |
| Chlorthalidone | 13 | $331 |
| Flecainide Acetate | 11 | $246 |
| Losartan Potassium | 12 | $236 |
| Lisinopril | 11 | $25 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Jacksonville
- Alan MillerJacksonville$547K
- Samer GarasJacksonville$258K
- Jose Nativi-NicolauJacksonville$125K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.